Business Context and Reporting Period
Company: Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A clinical-stage specialty pharmaceutical company focused on immune-inflammatory and rare diseases. The company operates via a US-India innovation corridor model.
Key Transaction: On August 15, 2025, the company completed a reverse merger with Vyome Therapeutics, Inc., renaming the entity to Vyome Holdings, Inc. and adopting the ticker symbol "HIND" on the Nasdaq Capital Market.
Segments: Biotechnology (clinical development) and Pharmaceutical Products (legacy licensing in India).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $319,714 | $256,944 |
| Net Loss | $(10,477,713) | $(1,447,461) |
| Operating Expenses | $10,671,341 | $1,201,310 |
| Research & Development | $588,258 | $285,391 |
| General & Administrative | $2,365,565 | $898,572 |
| Transactional Fees | $7,705,533 | $0 |
| Cash and Cash Equivalents (Dec 31, 2025) | $4,982,333 | $101,904 |
| Stockholders' Equity | $3,762,017 | $(4,391,033) |
Note: The 2025 Net Loss includes approximately $7.7 million in non-recurring transactional fees related to the merger.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 24% ($62,770) primarily due to milestone payments and service fees from the Luliconazole licensing agreement with Sun Pharma. The dandruff product service fee arrangement was terminated in December 2024.
- Expense Surge: Operating expenses increased by 788% year-over-year. This is driven by:
- Transactional Fees: $7.7 million in merger-related costs (cash and stock-based compensation to advisors).
- G&A Increase: $1.47 million increase due to legal, accounting, and audit fees associated with the merger and public company compliance, plus $577,128 in stock-based compensation.
- R&D Increase: $302,867 increase due to resuming R&D activities post-merger.
- Liquidity Improvement: Cash balance increased from $101,904 in 2024 to $4.98 million in 2025, funded by a concurrent private placement ($6.6 million) and an At-The-Market (ATM) offering ($1.3 million).
- Debt Elimination: All convertible notes and bridge notes were converted into equity during the merger, eliminating interest expense and fair value adjustments on debt for the remainder of the year.
Guidance, Outlook, and Risks
Outlook and Pipeline
- VT-1953 (Lead Program): Topical gel for malignant fungating wounds (MFW). Completed a Phase 2 investigator-initiated trial in December 2025 showing significant reduction in malodor (>75%) and pain (50%). Plans to discuss pivotal Phase 3 trial design with the FDA in the first half of 2026.
- VT-1908: Ophthalmic drops for steroid-sparing anterior uveitis. Pre-IND stage; anticipates enabling clinical trials by the second half of 2025.
- VB-1953: Topical gel for moderate to severe acne. Phase 2 completed; Phase 3-ready.
- Commercialization: No products approved for sale in the US. Revenue is currently derived solely from licensing agreements in India (Sun Pharma).
Liquidity and Capital Resources
Management believes existing cash ($4.98 million as of Dec 31, 2025) plus subsequent ATM proceeds (approx. $5.3 million raised Jan-Mar 2026) will fund operations for at least 15 months, including the initiation of the VT-1953 pivotal trial. However, additional funding will be required to complete the trial and develop other candidates.
Material Risks
- Internal Controls: The company identified material weaknesses in internal control over financial reporting as of December 31, 2025, including insufficient accounting expertise, lack of comprehensive policies, and segregation of duties issues. Remediation is underway.
- Going Concern: The company has incurred significant losses since inception and expects to continue doing so. Future operations depend on raising additional capital.
- Regulatory Approval: No products are approved for commercial sale in the US. Success depends on FDA approval of VT-1953 and VT-1908, which is uncertain.
- Customer Concentration: Substantially all revenue is derived from a single customer, Sun Pharma.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10M+ cash position (including post-year-end ATM proceeds) to fund the planned Phase 3 trial for VT-1953, which is capital-intensive.
- Merger Integration: Assess the progress of remediation for the identified material weaknesses in internal controls over financial reporting.
- Clinical Data: Review the full data package from the VT-1953 Phase 2 investigator-initiated trial to validate the reported efficacy on malodor and pain reduction.
- Revenue Sustainability: Confirm the status of the Sun Pharma licensing agreements, specifically the Luliconazole milestone payments, as the dandruff product agreement was terminated.
- Capital Requirements: Evaluate the timeline and terms for future equity or debt financing required to complete the Phase 3 trial and commercialize products.